| Bernadette L Koch, MD | |
|
3333 Burnet Ave Ml 5031, Cincinnati, OH 45229-3026 | |
| (513) 636-4251 | |
| (513) 636-8145 |
| Full Name | Bernadette L Koch |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 37 Years |
| Location | 3333 Burnet Ave Ml 5031, Cincinnati, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053324202 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085P0229X | Radiology - Pediatric Radiology | 35.057579 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Children's Hospital Medical Center | 8426955733 | 473 |
| Children's Hospital Medical Center | 8426955733 | 473 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
According to a study published by JAMA, weight gain during pregnancy (gestational weight gain) that was above or below the guideline recommendations was linked with a higher risk of adverse maternal and infant outcomes, compared with weight gain within recommended levels.
Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced that Senior Vice President, Dean Tozer and Vice President of Government Affairs and Health Economics, Therésa Dixon will speak on behalf of the Company at the 2010 World Stem Cell Summit, sharing their more than 30 years of combined industry experience with attendees.
Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).
In a mouse study designed to understand how chronic inflammation in sinusitis damages the sense of smell, scientists at Johns Hopkins say they were surprised to learn that the regeneration of olfactory tissue requires some of the same inflammatory processes and chemicals that create injury and loss of smell in the first place.
› Verified 8 days ago
| Entity Name | Children's Hospital Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609915784 PECOS PAC ID: 8426955733 Enrollment ID: O20100506000614 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
According to a study published by JAMA, weight gain during pregnancy (gestational weight gain) that was above or below the guideline recommendations was linked with a higher risk of adverse maternal and infant outcomes, compared with weight gain within recommended levels.
Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced that Senior Vice President, Dean Tozer and Vice President of Government Affairs and Health Economics, Therésa Dixon will speak on behalf of the Company at the 2010 World Stem Cell Summit, sharing their more than 30 years of combined industry experience with attendees.
Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).
In a mouse study designed to understand how chronic inflammation in sinusitis damages the sense of smell, scientists at Johns Hopkins say they were surprised to learn that the regeneration of olfactory tissue requires some of the same inflammatory processes and chemicals that create injury and loss of smell in the first place.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bernadette L Koch, MD 3333 Burnet Ave Ml 5031, Cincinnati, OH 45229-3026 Ph: (513) 636-4251 | Bernadette L Koch, MD 3333 Burnet Ave Ml 5031, Cincinnati, OH 45229-3026 Ph: (513) 636-4251 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.
According to a study published by JAMA, weight gain during pregnancy (gestational weight gain) that was above or below the guideline recommendations was linked with a higher risk of adverse maternal and infant outcomes, compared with weight gain within recommended levels.
Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced that Senior Vice President, Dean Tozer and Vice President of Government Affairs and Health Economics, Therésa Dixon will speak on behalf of the Company at the 2010 World Stem Cell Summit, sharing their more than 30 years of combined industry experience with attendees.
Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).
In a mouse study designed to understand how chronic inflammation in sinusitis damages the sense of smell, scientists at Johns Hopkins say they were surprised to learn that the regeneration of olfactory tissue requires some of the same inflammatory processes and chemicals that create injury and loss of smell in the first place.
› Verified 8 days ago
Preeyacha Pacharn, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3333 Burnet Ave, Ml 5031, Cincinnati, OH 45229 Phone: 513-636-4251 | |
Ifeoma Aguanunu, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman St, Cincinnati, OH 45219 Phone: 135-844-3915 | |
Dr. Marc R Mosbacher, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 601 Ivy Gtwy Ste 1100, Cincinnati, OH 45245 Phone: 513-751-2273 | |
Dr. Michael K. Shehata, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5520 Cheviot Rd, Cincinnati, OH 45247 Phone: 513-451-4033 Fax: 513-451-1356 | |
Dr. Ralph Vatner, M.D., PH.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman St, Cincinnati, OH 45219 Phone: 513-584-3494 Fax: 513-584-4007 | |
Dr. Rodney P Geier, MD Radiology Medicare: Medicare Enrolled Practice Location: 11140 Montgomery Rd, Cincinnati, OH 45249 Phone: 513-564-8520 Fax: 513-564-8539 | |
James M Meranus, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 375 Dixmyth Ave, Cincinnati, OH 45220 Phone: 513-965-8041 Fax: 513-965-8091 |